Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials

International Journal of Neuropsychopharmacology

Volumn 11, Issue 4, 2008, Pages 477-483

  Kawohl, Wolfram ^a   Giegling, Ina ^b   Mavrogiorgou, Paraskevi ^b   Pogarell, Oliver ^b   Mulert, Christoph ^b   Möller, Hans Jürgen ^b   Hegerl, Ulrich ^d   Rujescu, Dan ^b   Juckel, Georg ^c,e  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e ST JOSEF HOSPITAL   (Germany)

Author keywords

Auditory evoked potentials; Haplotype analysis; Nitric oxide synthase; Serotonin; Single nucleotide polymorphisms

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EVOKED AUDITORY RESPONSE; EXON; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; LOUDNESS; MALE; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ACOUSTIC STIMULATION; ADULT; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 44349147838     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008420     Document Type: Article

References (49)

1. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265.
2. Bredt DS, Snyder SH (1989). Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proceedings of the National Academy of Sciences USA 86, 9030-9033.
3. Bryan-Lluka LJ, Papacostas MH, Paczkowski FA, Wanstall JC (2004). Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT). British Journal of Pharmacology 143, 63-70.
4. Chanrion B, Mannoury la Cour C, Bertaso F, Lerner-Natoli M, Freissmuth M, Millan MJ, Bockaert J, Marin P (2007). Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity. Proceedings of the National Academy of Sciences USA 104, 8119-8124.
5. Chen TJ, Yu YW, Chen MC, Wang SY, Tsai SJ, Lee TW (2005). Serotonin dysfunction and suicide attempts in major depressives: an auditory event-related potential study. Neuropsychobiology 52, 28-36.
6. Chiavegatto S, Nelson RJ (2003). Interaction of nitric oxide and serotonin in aggressive behavior. Hormones and Behavior 44, 233-241.
7. Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH (1994). Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proceedings of the National Academy of Sciences USA 91, 4214-4218.
8. Doyle CA, Slater P (1997). Localization of neuronal and endothelial nitric oxide synthase isoforms in human hippocampus. Neuroscience 76, 387-395.
9. Ehlers CL, Wall TL, Chaplin RI (1991). Long latency event-related potentials in rats: effects of dopaminergic and serotonergic depletions. Pharmacology Biochemistry and Behavior 38, 789-793.
10. First M, Spitzer R, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV Axis I and II Disorders. Washington, DC: American Psychiatric Press.
11. Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stotz G, Kuss HJ, Mavrogiorgou P, Hegerl U (2000). The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berlin) 148, 404-411.
12. Harkin A, Connor TJ, Burns MP, Kelly JP (2004). Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. European Neuropsychopharmacology 14, 274-281.
13. Harkin A, Connor TJ, Walsh M, St John N, Kelly JP (2003). Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44, 616-623.
14. Hegerl U, Gallinat J, Juckel G (2001). Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? Journal of Affective Disorders 62, 93-100.
15. Hegerl U, Juckel G (1993). Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biological Psychiatry 33, 173-187.
16. Hegerl U, Juckel G (1994). Auditory evoked dipole source activity: indicator of central serotonergic dysfunction in psychiatric patients? Pharmacopsychiatry 27, 75-78.
17. Hegerl U, Juckel G (2000). Identifying psychiatric patients with serotonergic dysfunctions by event-related potentials. World Journal of Biological Psychiatry 1, 112-118.
18. Hegerl U, Juckel G, Schmidt LG, Rommelspacher H (1996). Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects. Psychiatry Research 63, 47-55.
19. Inan SY, Yalcin I, Aksu F (2004). Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacology Biochemistry and Behavior 77, 457-464.
20. Iuras A, Telles MM, Bertoncini CR, Ko GM, de Andrade IS, Silveira VL, Ribeiro EB (2005). Central administration of a nitric oxide precursor abolishes both the hypothalamic serotonin release and the hypophagia induced by interleukin-1beta in obese Zucker rats. Regulatory Peptides 124, 145-150.
21. Jacobs BL, Azmitia EC (1992). Structure and function of the brain serotonin system. Physiological Reviews 72, 165-229.
22. Juckel G, Csepe V, Molnar M, Hegerl U, Karmos G (1996). Intensity dependence of auditory evoked potentials in behaving cats. Electroencephalography and Clinical Neurophysiology 100, 527-537.
23. Juckel G, Gallinat J, Riedel M, Sokullu S, Schulz C, Moller HJ, Muller N, Hegerl U (2003). Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. Schizophrenia Research 64, 115-124.
24. Juckel G, Hegerl U, Molnar M, Csepe V, Karmos G (1999). Auditory evoked potentials reflect serotonergic neuronal activity - a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 21, 710-716.
25. Juckel G, Molnar M, Hegerl U, Csepe V, Karmos G (1997). Auditory-evoked potentials as indicator of brain serotonergic activity - first evidence in behaving cats. Biological Psychiatry 41, 1181-1195.
26. 3H]L-NG-nitro-arginine binding in rat brain. Neuropharmacology 34, 63-73.
27. Kilic F, Murphy DL, Rudnick G (2003). A human serotonin transporter mutation causes constitutive activation of transport activity. Molecular Pharmacol 64, 440-446.
28. Lewis DA, Campbell MJ, Foote SL, Morrison JH (1986). The monoaminergic innervation of primate neocortex. Human Neurobiology 5, 181-188.
29. O'Dell TJ, Huang PL, Dawson TM, Dinerman JL, Snyder SH, Kandel ER, Fishman MC (1994). Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science 265, 542-546.
30. O'Neill BV, Croft RJ, Leung S, Guille V, Galloway M, Phan KL, Nathan PJ (2006). Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans. Psychopharmacology (Berlin) 188, 92-99.
31. Pineda JA, Holmes TC, Foote SL (1991). Intensity-amplitude relationships in monkey event-related potentials: parallels to human augmenting-reducing responses. Electroencephalography and Clinical Neurophysiology 78, 456-465.
32. Pitsikas N, Rigamonti AE, Cella SG, Sakellaridis N, Muller EE (2005). The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat. Neurobiology of Aging 26, 259-264.
33. Pogarell O, Tatsch K, Juckel G, Hamann C, Mulert C, Popperl G, Folkerts M, Chouker M, Riedel M, Zaudig M, Moller HJ, Hegerl U (2004). Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology 29, 1910-1917.
34. Prast H, Philippu A (2001). Nitric oxide as modulator of neuronal function. Progress in Neurobiology 64, 51-68.
35. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP, Wienker T, Topner T, Fritzen S, Walter U et al. (2006a). A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Molecular Psychiatry 11, 286-300.
36. Reif A, Schmitt A, Fritzen S, Chourbaji S, Bartsch C, Urani A, Wycislo M, Mossner R, Sommer C, Gass P, Lesch KP (2004). Differential effect of endothelial nitric oxide synthase (NOS-III) on the regulation of adult neurogenesis and behaviour. European Journal of Neuroscience 20, 885-895.
37. Reif A, Strobel A, Jacob CP, Herterich S, Freitag CM, Topner T, Mossner R, Fritzen S, Schmitt A, Lesch KP (2006b). A NOS-III haplotype that includes functional polymorphisms is associated with bipolar disorder. International Journal of Neuropsychopharmacology 9, 13-20.
38. Rice JP, Reich T, Bucholz KK, Neuman RJ, Fishman R, Rochberg N, Hesselbrock VM, Nurnberger Jr. JI, Schuckit MA, Begleiter H (1995). Comparison of direct interview and family history diagnoses of alcohol dependence. Alcoholism: Clinical and Experimental Research 19, 1018-1023.
39. Rujescu D, Giegling I, Mandelli L, Schneider B, Hartmann AM, Schnabel A, Maurer K, Möller HJ, Serretti A (2007). NOS-I and -III gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. American Journal of Medical Genetics, B: Neuropsychiatric Genetics 147, 42-48.
40. Saur D, Vanderwinden JM, Seidler B, Schmid RM, De Laet MH, Allescher HD (2004). Single-nucleotide promoter polymorphism alters transcription of neuronal nitric oxide synthase exon 1c in infantile hypertrophic pyloric stenosis. Proceedings of the National Academy of Sciences USA 101, 1662-1667.
41. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002). Score tests for association between traits and haplotypes when linkage phase is ambiguous. American Journal of Human Genetics 70, 425-434.
42. Segieth J, Pearce B, Fowler L, Whitton PS (2001). Regulatory role of nitric oxide over hippocampal 5-HT release in vivo. Naunyn Schmiedeberg's Archives of Pharmacology 363, 302-306.
43. Smith JC, Whitton PS (2000). Nitric oxide modulates N-methyl-D-aspartate-evoked serotonin release in the raphe nuclei and frontal cortex of the freely moving rat. Neuroscience Letters 291, 5-8.
44. Snyder SH, Ferris CD (2000). Novel neurotransmitters and their neuropsychiatric relevance. American Journal of Psychiatry 157, 1738-1751.
45. Straub VA, Grant J, O'Shea M, Benjamin PR (2007). Modulation of serotonergic neurotransmission by nitric oxide. Journal of Neurophysiology 97, 1088-1099.
46. Trabace L, Kendrick KM (2000). Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. Journal of Neurochemistry 75, 1664-1674.
47. von Knorring L, Perris C (1981). Biochemistry of the augmenting-reducing response in visual evoked potentials. Neuropsychobiology 7, 1-8.
48. Wittchen H, Zaudig M, Fydrich T (1997). Strukturiertes Klinisches Interview für DSM-IV, Achse I und II. Goettingen: Hogrefe.
49. Yun HY, Dawson VL, Dawson TM (1997). Nitric oxide in health and disease of the nervous system. Molecular Psychiatry 2, 300-310.